Serina Therapeutics Inc (SER)

$4.81 +0.06 (1.26%)
Market Cap 42.77M
Revenue (ttm) 140,000.00
Net Income (ttm) -14.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,571.43%
Debt to Equity Ratio 0.00
Volume 41,400
Avg Vol 30,598
Day's Range N/A - N/A
Shares Out 8.89M
Stochastic %K 26%
Beta 0.94
Analysts Strong Buy
Price Target N/A

Latest News on SER

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 15, 2025, 4:05 PM EST - 4 days ago

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Jan 14, 2025, 5:25 PM EST - 5 days ago

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Dec 16, 2024, 6:00 AM EST - 5 weeks ago

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Dec 11, 2024, 6:05 AM EST - 5 weeks ago

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Dec 2, 2024, 5:22 PM EST - 6 weeks ago

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 12, 2024, 5:00 PM EST - 2 months ago

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

Nov 11, 2024, 5:40 PM EST - 2 months ago

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 6:42 PM EDT - 4 months ago

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Aug 9, 2024, 4:15 PM EDT - 5 months ago

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Jul 29, 2024, 8:30 AM EDT - 6 months ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

Jul 18, 2024, 5:00 PM EDT - 6 months ago

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

May 14, 2024, 4:05 PM EDT - 8 months ago

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman

Apr 17, 2024, 4:05 PM EDT - 9 months ago

Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

Mar 26, 2024, 5:04 PM EDT - 10 months ago

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

Mar 22, 2024, 5:27 PM EDT - 10 months ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE

Feb 27, 2024, 3:19 PM EST - 11 months ago

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 1 year ago

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement

Aug 30, 2023, 7:00 AM EDT - 1 year ago

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 4:05 PM EDT - 1 year ago

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock

Jul 24, 2023, 6:28 PM EDT - 1 year ago

AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock

AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock

Jul 21, 2023, 5:32 PM EDT - 1 year ago

AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock

AgeX Therapeutics Announces Appeal of NYSE American Determination

May 23, 2023, 4:05 PM EDT - 1 year ago

AgeX Therapeutics Announces Appeal of NYSE American Determination

CORRECTING and REPLACING NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE)

May 17, 2023, 5:31 PM EDT - 1 year ago

CORRECTING and REPLACING NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE)

NYSE American to Suspend Trading Immediately in AgeX Therapeutics, Inc. (AGE) and Commence Delisting Proceedings

May 17, 2023, 4:34 PM EDT - 1 year ago

NYSE American to Suspend Trading Immediately in AgeX Therapeutics, Inc. (AGE) and Commence Delisting Proceedings

AgeX Therapeutics Reports First Quarter 2023 Financial Results

May 12, 2023, 4:05 PM EDT - 1 year ago

AgeX Therapeutics Reports First Quarter 2023 Financial Results

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

Apr 26, 2023, 4:05 PM EDT - 1 year ago

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results

Mar 31, 2023, 4:05 PM EDT - 1 year ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results

AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Nov 25, 2022, 3:41 PM EST - 2 years ago

AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

AgeX Therapeutics Reports Third Quarter 2022 Financial Results

Nov 10, 2022, 4:05 PM EST - 2 years ago

AgeX Therapeutics Reports Third Quarter 2022 Financial Results

AgeX Therapeutics Reports Second Quarter 2022 Financial Results

Aug 12, 2022, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Reports Second Quarter 2022 Financial Results

Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

May 18, 2022, 8:30 AM EDT - 2 years ago

Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

Early-Stage Investments for Turkish Metaverse Platform MetaAge Nears $1-Million Mark

May 16, 2022, 4:00 AM EDT - 2 years ago

Early-Stage Investments for Turkish Metaverse Platform MetaAge Nears $1-Million Mark

AgeX Therapeutics Reports First Quarter 2022 Financial Results

May 13, 2022, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Reports First Quarter 2022 Financial Results

AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results

Mar 29, 2022, 4:05 PM EDT - 3 years ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results

AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders

Dec 14, 2021, 8:30 AM EST - 3 years ago

AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders

AgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

Nov 30, 2021, 8:30 AM EST - 3 years ago

AgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

AgeX Therapeutics Reports Third Quarter 2021 Financial Results

Nov 12, 2021, 4:05 PM EST - 3 years ago

AgeX Therapeutics Reports Third Quarter 2021 Financial Results

AgeX Therapeutics Reports Second Quarter 2021 Financial Results

Aug 13, 2021, 4:05 PM EDT - 3 years ago

AgeX Therapeutics Reports Second Quarter 2021 Financial Results

AgeX Therapeutics and LyGenesis Terminate Merger Negotiations

Jul 23, 2021, 4:15 PM EDT - 3 years ago

AgeX Therapeutics and LyGenesis Terminate Merger Negotiations

AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May 17, 2021, 4:05 PM EDT - 3 years ago

AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

AgeX Therapeutics: New LyGenesis Merger May Unlock Much-Needed Value

Apr 14, 2021, 2:47 PM EDT - 4 years ago

AgeX Therapeutics: New LyGenesis Merger May Unlock Much-Needed Value

AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update

Mar 31, 2021, 4:05 PM EDT - 4 years ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update

AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer

Mar 12, 2021, 8:00 AM EST - 4 years ago

AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer

AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity

Mar 10, 2021, 8:00 AM EST - 4 years ago

AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity

AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

Mar 2, 2021, 8:00 AM EST - 4 years ago

AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only

Dec 22, 2020, 3:08 PM EST - 4 years ago

AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only

AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Nov 16, 2020, 4:05 PM EST - 4 years ago

AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome

Oct 28, 2020, 8:00 AM EDT - 4 years ago

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome